The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.
 
Yasmeen Rauf
No Relationships to Disclose
 
Rachel Hufsey
No Relationships to Disclose
 
Kathy Robinson
No Relationships to Disclose
 
John H. Suh
Consulting or Advisory Role - Novocure; Philips, Inc.
 
Samuel T. Chao
Stock and Other Ownership Interests - Incyte (I)
Honoraria - Varian Medical Systems
Consulting or Advisory Role - Blue Earth Diagnostics
 
Erin Sennett Murphy
No Relationships to Disclose
 
Jennifer S. Yu
No Relationships to Disclose
 
David M. Peereboom
Honoraria - Elsevier
Consulting or Advisory Role - Orbus Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Mylan (Inst); Neonc Technologies (Inst); Novartis (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - Stemline Therapeutics
 
Manmeet Singh Ahluwalia
Stock and Other Ownership Interests - CytoDyn; doctible; MimiVax
Honoraria - Elsevier; Peerview; Prime Education; Prime Oncology
Consulting or Advisory Role - Abbvie; Apollomics; Bayer; Celularity; Flatiron Health; FORMA Therapeutics; GlaxoSmithKline; InSightec; KIYATEC; Novocure; Nuvation Bio; Tocagen; Varian Medical Systems
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst)
 
Wei Wei
No Relationships to Disclose